BRPI9911326B8 - análogos macrocíclicos e métodos para seu uso e preparação - Google Patents
análogos macrocíclicos e métodos para seu uso e preparaçãoInfo
- Publication number
- BRPI9911326B8 BRPI9911326B8 BRPI9911326A BR9911326A BRPI9911326B8 BR PI9911326 B8 BRPI9911326 B8 BR PI9911326B8 BR PI9911326 A BRPI9911326 A BR PI9911326A BR 9911326 A BR9911326 A BR 9911326A BR PI9911326 B8 BRPI9911326 B8 BR PI9911326B8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- preparation
- analogues
- macrocyclic
- cell
- Prior art date
Links
- 229930195695 Halichondrin Natural products 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000002927 anti-mitotic effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000011278 mitosis Effects 0.000 abstract 1
- 230000000394 mitotic effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8968298P | 1998-06-17 | 1998-06-17 | |
| US60/089,682 | 1998-06-17 | ||
| PCT/US1999/013677 WO1999065894A1 (en) | 1998-06-17 | 1999-06-16 | Macrocyclic analogs and methods of their use and preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR9911326A BR9911326A (pt) | 2001-04-03 |
| BR9911326B1 BR9911326B1 (pt) | 2015-01-06 |
| BRPI9911326B8 true BRPI9911326B8 (pt) | 2021-05-25 |
Family
ID=22219026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9911326A BRPI9911326B8 (pt) | 1998-06-17 | 1999-06-16 | análogos macrocíclicos e métodos para seu uso e preparação |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US6214865B1 (https=) |
| EP (4) | EP2272839B1 (https=) |
| JP (1) | JP4454151B2 (https=) |
| KR (1) | KR100798600B1 (https=) |
| CN (1) | CN1216051C (https=) |
| AT (1) | ATE502932T1 (https=) |
| AU (1) | AU762998B2 (https=) |
| BE (1) | BE2011C028I2 (https=) |
| BR (1) | BRPI9911326B8 (https=) |
| CA (3) | CA2335300C (https=) |
| CY (2) | CY1111516T1 (https=) |
| DE (2) | DE69943296D1 (https=) |
| DK (1) | DK1087960T3 (https=) |
| FR (1) | FR11C0038I2 (https=) |
| HU (1) | HU227912B1 (https=) |
| IL (1) | IL139960A0 (https=) |
| LU (1) | LU91854I2 (https=) |
| NO (5) | NO328280B1 (https=) |
| NZ (1) | NZ508597A (https=) |
| PT (1) | PT1087960E (https=) |
| WO (1) | WO1999065894A1 (https=) |
| ZA (1) | ZA200007159B (https=) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097648B2 (en) * | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| JP4454151B2 (ja) * | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 大環状類似体及びそれらの使用並びに調製方法 |
| DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
| EP1531846A4 (en) * | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| KR101208266B1 (ko) | 2002-03-22 | 2012-12-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤미아스텔린 유도체 및 이의 용도 |
| US20050075395A1 (en) * | 2003-05-28 | 2005-04-07 | Gary Gordon | Continuous dosing regimen |
| CA2526385C (en) * | 2003-05-29 | 2008-07-22 | Abbott Laboratories | Continuous dosing regimen with abt-751 |
| WO2005011589A2 (en) * | 2003-07-29 | 2005-02-10 | Eisai Co., Ltd. | Drug delivery methods and devices |
| CA2822994C (en) * | 2004-06-03 | 2016-09-27 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin b |
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| US20060045846A1 (en) * | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
| US20060154312A1 (en) * | 2004-12-09 | 2006-07-13 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using halichondrin B analogs |
| BRPI0817909B1 (pt) * | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| CA2720632C (en) * | 2008-04-04 | 2016-12-20 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
| WO2010113983A1 (ja) | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| RU2476216C1 (ru) * | 2009-03-30 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Липосомальная композиция |
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| US8765974B2 (en) * | 2009-04-14 | 2014-07-01 | Nissan Chemical Industries, Ltd. | Method for producing tetrahydropyran compound and intermediate thereof |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| RU2579511C2 (ru) | 2010-01-26 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные фуро[3,2-в]пирана, применимые в синтезе аналогов |
| EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| WO2013078559A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| JP2015501818A (ja) | 2011-12-16 | 2015-01-19 | アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． | ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法 |
| CA2860446C (en) * | 2011-12-29 | 2017-01-10 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
| US9278979B2 (en) | 2012-03-30 | 2016-03-08 | Alphora Research Inc. | Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein |
| RU2689977C2 (ru) | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| CA2909209A1 (en) | 2013-05-15 | 2014-11-20 | Alphora Research Inc. | 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof |
| BR112015029386B1 (pt) | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| EP3016957A4 (en) * | 2013-07-03 | 2016-11-30 | Alphora Res Inc | SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS |
| CN103483352A (zh) * | 2013-10-18 | 2014-01-01 | 李友香 | 抗肿瘤的药用原料药 |
| BR112016009452B1 (pt) | 2013-11-04 | 2022-06-07 | Eisai R&D Management Co., Ltd | Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários |
| EP3077399B1 (en) | 2013-12-06 | 2019-02-20 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin b analogs |
| CN104860978A (zh) * | 2014-02-20 | 2015-08-26 | 正大天晴药业集团股份有限公司 | 软海绵素b类似物的合成中间体 |
| TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Ａｌｐｈｏｒａ研發股份有限公司 | （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物 |
| US20170100367A1 (en) | 2014-05-28 | 2017-04-13 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| US10556910B2 (en) | 2014-06-30 | 2020-02-11 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| US10208058B2 (en) * | 2014-09-09 | 2019-02-19 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof |
| CN105713031B (zh) * | 2014-12-05 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种用于制备艾日布林的中间体及其制备方法 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| AU2016226157B2 (en) | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| MX392296B (es) * | 2015-05-07 | 2025-03-24 | Eisai R&D Man Co Ltd | Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina. |
| WO2016182850A1 (en) | 2015-05-08 | 2016-11-17 | Albany Molecular Research, Inc. | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| CN108601760A (zh) * | 2016-02-12 | 2018-09-28 | 卫材R&D管理有限公司 | 艾日布林的合成中的中间体及相关的合成方法 |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| WO2017203459A1 (en) | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| KR102404629B1 (ko) | 2016-06-30 | 2022-06-02 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체 |
| WO2018071792A1 (en) | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| WO2018096478A2 (en) | 2016-11-23 | 2018-05-31 | Dr. Reddy’S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| KR101880939B1 (ko) | 2017-01-02 | 2018-08-17 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| US10865212B2 (en) | 2017-01-02 | 2020-12-15 | Yonsung Fine Chemical Co.. Ltd. | Intermediate for preparing eribulin mesylate and process for preparing the same |
| KR101991710B1 (ko) | 2017-12-14 | 2019-06-21 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| CN108341738B (zh) * | 2017-01-24 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的方法及其中间体 |
| CN108341828B (zh) * | 2017-01-24 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的方法及其中间体 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| SMT202200455T1 (it) | 2017-04-05 | 2023-01-13 | Harvard College | Composto macrociclico e relativi usi |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| WO2019010363A1 (en) | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | HALICHONDRINES SYNTHESIS |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
| CN109694379B (zh) * | 2017-10-24 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的中间体及其制备方法 |
| US11142509B2 (en) | 2017-11-09 | 2021-10-12 | Yonsung Fine Chemical Co., Ltd. | Intermediate for preparing eribulin mesylate and process for preparing the same |
| WO2019099646A1 (en) | 2017-11-15 | 2019-05-23 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2019102490A1 (en) | 2017-11-21 | 2019-05-31 | Natco Pharma Limited | Intermediates for the preparation of eribulin thereof |
| IL275729B2 (en) | 2018-01-03 | 2023-09-01 | Eisai R&D Man Co Ltd | Prins reaction and compounds useful in the synthesis of helicondrin macrolides and their analogs |
| WO2019211877A1 (en) | 2018-05-03 | 2019-11-07 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin b |
| WO2020008382A1 (en) * | 2018-07-04 | 2020-01-09 | Dr. Reddy’S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| WO2020016847A2 (en) * | 2018-07-20 | 2020-01-23 | Dr. Reddy’S Laboratories Limited | Purification process for preparation of eribulin and intermediates thereof |
| CN113166096A (zh) * | 2018-10-09 | 2021-07-23 | 雷迪博士实验室有限公司 | 制备艾立布林的方法及其中间体 |
| US12522611B2 (en) * | 2018-11-28 | 2026-01-13 | Natco Pharma Limited | Process for the preparation of high pure Eribulin and its Mesylate salt |
| US12398105B2 (en) | 2018-12-20 | 2025-08-26 | Auransa Inc. | Analogues of pentamidine and uses therefor |
| US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
| US12247239B2 (en) | 2019-06-21 | 2025-03-11 | Council Of Scientific & Industrial Research | Chemo-enzymatic process for the preparation of homopropargylic alcohol |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| CN113135876B (zh) * | 2020-01-16 | 2024-05-17 | 南通诺泰生物医药技术有限公司 | 艾日布林及其中间体的制备方法 |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| KR102377262B1 (ko) | 2020-05-11 | 2022-03-22 | 연성정밀화학(주) | 결정성 에리불린 염 |
| IL279168B (en) * | 2020-12-02 | 2022-04-01 | Finetech Pharmaceutical Ltd | A process for the preparation of eribulin |
| CN113354659B (zh) | 2021-06-08 | 2022-04-08 | 江苏慧聚药业股份有限公司 | 甲磺酸艾日布林的合成 |
| CA3225975A1 (en) * | 2021-07-22 | 2023-01-26 | Shanghai Senhui Medicine Co., Ltd. | Drug conjugate of eribulin derivative |
| WO2023212746A2 (en) * | 2022-04-30 | 2023-11-02 | William Marsh Rice University | A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b |
| CN118356507A (zh) * | 2023-01-17 | 2024-07-19 | 成都百利多特生物药业有限责任公司 | 一种艾日布林类药物的偶联物 |
| EP4725969A1 (en) | 2023-06-09 | 2026-04-15 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof |
| CN118834221B (zh) * | 2023-08-08 | 2025-10-21 | 浙江星月药物科技有限公司 | 一种软海绵素b类似物 |
| TW202518024A (zh) | 2023-10-13 | 2025-05-01 | 日商衛材R&D企管股份有限公司 | 抗體－藥物軛合物代謝物 |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
| WO2025228172A1 (zh) * | 2024-04-28 | 2025-11-06 | 上海拓济医药有限责任公司 | 艾日布林衍生物及其抗体药物偶联物和医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| US5338865A (en) * | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| GB9206244D0 (en) * | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
| US5426194A (en) * | 1993-01-19 | 1995-06-20 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 1 |
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| JP4454151B2 (ja) * | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 大環状類似体及びそれらの使用並びに調製方法 |
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| BRPI0817909B1 (pt) | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| CN101910180A (zh) | 2007-11-16 | 2010-12-08 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应 |
| CA2720632C (en) | 2008-04-04 | 2016-12-20 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
| RU2579511C2 (ru) | 2010-01-26 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные фуро[3,2-в]пирана, применимые в синтезе аналогов |
-
1999
- 1999-06-16 JP JP2000554719A patent/JP4454151B2/ja not_active Expired - Lifetime
- 1999-06-16 CA CA002335300A patent/CA2335300C/en not_active Expired - Lifetime
- 1999-06-16 EP EP10010773A patent/EP2272839B1/en not_active Expired - Lifetime
- 1999-06-16 HU HU0103357A patent/HU227912B1/hu active Protection Beyond IP Right Term
- 1999-06-16 DE DE69943296T patent/DE69943296D1/de not_active Expired - Lifetime
- 1999-06-16 EP EP99928746A patent/EP1087960B1/en not_active Expired - Lifetime
- 1999-06-16 PT PT99928746T patent/PT1087960E/pt unknown
- 1999-06-16 EP EP10010774A patent/EP2272840B1/en not_active Expired - Lifetime
- 1999-06-16 DE DE201112100031 patent/DE122011100031I1/de active Pending
- 1999-06-16 EP EP10010772A patent/EP2277873B1/en not_active Expired - Lifetime
- 1999-06-16 DK DK99928746.9T patent/DK1087960T3/da active
- 1999-06-16 AU AU45739/99A patent/AU762998B2/en not_active Expired
- 1999-06-16 KR KR1020007014229A patent/KR100798600B1/ko not_active Expired - Lifetime
- 1999-06-16 NZ NZ508597A patent/NZ508597A/en not_active IP Right Cessation
- 1999-06-16 WO PCT/US1999/013677 patent/WO1999065894A1/en not_active Ceased
- 1999-06-16 BR BRPI9911326A patent/BRPI9911326B8/pt not_active IP Right Cessation
- 1999-06-16 CA CA2632433A patent/CA2632433C/en not_active Expired - Lifetime
- 1999-06-16 CA CA2755266A patent/CA2755266C/en not_active Expired - Lifetime
- 1999-06-16 IL IL13996099A patent/IL139960A0/xx active Protection Beyond IP Right Term
- 1999-06-16 US US09/334,488 patent/US6214865B1/en not_active Expired - Lifetime
- 1999-06-16 AT AT99928746T patent/ATE502932T1/de active
- 1999-06-16 CN CN99809658XA patent/CN1216051C/zh not_active Expired - Lifetime
-
2000
- 2000-10-02 US US09/677,485 patent/US6365759B1/en not_active Expired - Lifetime
- 2000-12-04 ZA ZA200007159A patent/ZA200007159B/en unknown
- 2000-12-12 NO NO20006316A patent/NO328280B1/no not_active IP Right Cessation
-
2001
- 2001-04-26 US US09/843,617 patent/US6469182B1/en not_active Expired - Lifetime
-
2009
- 2009-10-26 NO NO20093217A patent/NO331183B1/no active Protection Beyond IP Right Term
-
2010
- 2010-08-12 US US12/855,412 patent/US8148554B2/en not_active Expired - Fee Related
-
2011
- 2011-06-01 CY CY20111100530T patent/CY1111516T1/el unknown
- 2011-08-12 CY CY2011010C patent/CY2011010I1/el unknown
- 2011-08-17 LU LU91854C patent/LU91854I2/fr unknown
- 2011-09-02 BE BE2011C028C patent/BE2011C028I2/fr unknown
- 2011-09-09 FR FR11C0038C patent/FR11C0038I2/fr active Active
- 2011-09-16 NO NO2011018C patent/NO2011018I1/no unknown
- 2011-12-14 NO NO2011026C patent/NO2011026I2/no unknown
-
2022
- 2022-06-03 NO NO2022019C patent/NO2022019I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI9911326B8 (pt) | análogos macrocíclicos e métodos para seu uso e preparação | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| BENCOSME et al. | Electron microscopy of the pancreatic islets | |
| BR9811249A (pt) | Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma | |
| BR0314353A (pt) | Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio | |
| BR9813827A (pt) | Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral | |
| BR0113358A (pt) | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável | |
| BR0109705A (pt) | Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b | |
| BR0107147A (pt) | Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações | |
| PA8515701A1 (es) | Compuestos, composiciones farmaceuticas y metodos para inhibir kinasas proteinicas | |
| BR9808703A (pt) | Composição que fornece medicamento solúvel emágua de dissolução relativamente lenta e usosublingual | |
| ES2193391T3 (es) | Antagonistas muscarinicos. | |
| BR9810340A (pt) | Sìntese e uso de compostos retinóides com atividades de hormÈnio negativo e/ou antagonistas | |
| BR9810729A (pt) | Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante | |
| GT199700089A (es) | Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido. | |
| BRPI0206636B8 (pt) | composição e atividade antiviral de derivados de piperazina azaindoloxoacéticos substituídos, composições farmacêuticas que os contêm e usos | |
| BR9913945A (pt) | Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos | |
| PT1010688E (pt) | 2-fenil-1-(3,4-di-hidroxi-5-nitrofenil)-1-etanonas substituidas seu uso no tratamento de algumas perturbacoes do sistema nervoso central e periferico e formulacoes do sistema nervoso central e periferico e formulacoes farmaceuticas que as contem | |
| BR0006675A (pt) | Derivados de indoloxoacetil piperazina antivirais | |
| BR0108930A (pt) | Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente | |
| BR9803704A (pt) | Quinazolina-4-ona como antagonistas do ampa. | |
| BR0316296A (pt) | Compostos lapacone e seus métodos de uso | |
| BR0210630A (pt) | Sistema fornecedor de liberação prolongada | |
| ATE192338T1 (de) | Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen | |
| BR9811458A (pt) | "sistema solvente para penetração melhorada de compostos farmacêuticos" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP) Free format text: TRANSFERIDO DE: EISAI CO., LTD. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/01/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 16/06/2019 |